ATE504557T1 - Aspirin-ausgelöste lipidmediatoren - Google Patents

Aspirin-ausgelöste lipidmediatoren

Info

Publication number
ATE504557T1
ATE504557T1 AT06022386T AT06022386T ATE504557T1 AT E504557 T1 ATE504557 T1 AT E504557T1 AT 06022386 T AT06022386 T AT 06022386T AT 06022386 T AT06022386 T AT 06022386T AT E504557 T1 ATE504557 T1 AT E504557T1
Authority
AT
Austria
Prior art keywords
aspirin
lipid mediators
released lipid
released
mediators
Prior art date
Application number
AT06022386T
Other languages
English (en)
Inventor
Clary B Clish
Charles N Serhan
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Application granted granted Critical
Publication of ATE504557T1 publication Critical patent/ATE504557T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/64—Fats; Fatty oils; Ester-type waxes; Higher fatty acids, i.e. having at least seven carbon atoms in an unbroken chain bound to a carboxyl group; Oxidised oils or fats
    • C12P7/6436—Fatty acid esters
    • C12P7/6445—Glycerides
    • C12P7/6472—Glycerides containing polyunsaturated fatty acid [PUFA] residues, i.e. having two or more double bonds in their backbone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT06022386T 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren ATE504557T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18307800P 2000-02-16 2000-02-16
US23881400P 2000-10-06 2000-10-06

Publications (1)

Publication Number Publication Date
ATE504557T1 true ATE504557T1 (de) 2011-04-15

Family

ID=26878731

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06022386T ATE504557T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren
AT01910912T ATE344226T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01910912T ATE344226T1 (de) 2000-02-16 2001-02-16 Aspirin-ausgelöste lipidmediatoren

Country Status (11)

Country Link
US (5) US6670396B2 (de)
EP (2) EP1762557B1 (de)
JP (5) JP4932116B2 (de)
CN (4) CN102010324B (de)
AT (2) ATE504557T1 (de)
AU (4) AU3846801A (de)
CA (1) CA2400462C (de)
DE (2) DE60144401D1 (de)
IL (1) IL151299A0 (de)
MX (1) MXPA02007915A (de)
WO (1) WO2001060778A2 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
ITMI20010129A1 (it) 2001-01-25 2002-07-25 Pharmacia & Upjohn Spa Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco
JP2005506285A (ja) * 2001-02-27 2005-03-03 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン 表皮成長因子受容体を活性化するレチノイド療法、石鹸および他の刺激物による副作用を防止する目的での天然ｅｇｆｒ阻害剤の使用
ES2344814T3 (es) 2001-03-02 2010-09-07 The Brigham And Women's Hospital Analogos de lipoxina como nuevos inhibidores de la angiogenesis.
AU2002252175A1 (en) * 2001-03-02 2002-09-19 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
GB0111282D0 (en) * 2001-05-09 2001-06-27 Laxdale Ltd Potentiation of therapeutic effects of fatty acids
EP1407767A4 (de) * 2001-06-18 2007-01-24 Yamada Sachiko Pparg-agonistische medizinische zusammensetzungen
ITMI20012384A1 (it) * 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
AU2002365167A1 (en) * 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
WO2003051350A1 (en) * 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
ES2527753T3 (es) * 2002-04-01 2015-01-29 University Of Southern California Eicosanoides trihidroxi poliinsaturados
US7902257B2 (en) * 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
WO2003105776A2 (en) * 2002-06-17 2003-12-24 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
JP4845378B2 (ja) * 2002-08-12 2011-12-28 ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド レソルビン：治療処置用のバイオテンプレート
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
EP2283837A3 (de) * 2002-09-27 2011-04-20 Martek Biosciences Corporation Docosahexaensäure zur Behandlung von subklinischen Entzündungen
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
DE602004029039D1 (de) * 2003-07-07 2010-10-21 Hills Pet Nutrition Inc Zusammensetzungen für einen verbesserten oxidationsstatus bei katzen
US20050238589A1 (en) * 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20060002985A1 (en) * 2004-07-02 2006-01-05 Zicker Steven C Compositions and methods for decreasing age-related deterioration in mental activities in companion animals
EP1799196B1 (de) * 2004-10-08 2016-06-22 Forward Pharma A/S Pharmazeutische zusammensetzung mit kontrollierter freisetzung mit einem fumarsäureester
US7893106B2 (en) * 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
US20090318394A1 (en) * 2004-11-19 2009-12-24 Julie Nauroth Long Chain Polyunsaturated Fatty Acids and Methods of Making and Using the Same
EA010802B1 (ru) * 2004-11-19 2008-12-30 Мартек Байосайенсиз Корпорейшн Оксилипины из полиненасыщенных жирных кислот с длинной цепью и способы их получения и применения
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US20060194723A1 (en) * 2005-02-28 2006-08-31 Rabinoff Michael D Novel medication treatment and delivery strategies for Alzheimer's Disease, other disorders with memory impairment, and possible treatment strategies for memory improvement
US8273792B2 (en) * 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
EP1954291A1 (de) 2005-11-18 2008-08-13 Trustees Of Boston University Behandlung und prävention von knochenschwund mithilfe von resolvinen
EP1983977A4 (de) * 2006-01-31 2011-11-30 Martek Biosciences Corp Oxylipine aus stearidonsäure und gamma-linolensäure sowie verfahren zu ihrer herstellung und verwendung
US20070254897A1 (en) * 2006-04-28 2007-11-01 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of cardiovascular disease
US20100035989A1 (en) * 2006-07-19 2010-02-11 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis
EP2131833A2 (de) * 2006-10-26 2009-12-16 Resolvyx Pharmaceuticals, Inc. Verwendung von resolvinen zur hemmung von knochenschwund
WO2008070129A2 (en) * 2006-12-05 2008-06-12 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of inflammatory disease
EP2120916A4 (de) * 2007-02-05 2010-07-28 Children Youth And Women S Hea Modulatoren antigenabhängiger t-zellproliferation
US20110190389A1 (en) * 2007-02-20 2011-08-04 Linda Arterburn Oxylipins from long chain polyunsaturated fatty acids and methods of making and using the same
WO2009017802A1 (en) 2007-08-01 2009-02-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Nitro-fattyacid modulation of type ii diabetes
WO2009038671A2 (en) * 2007-09-14 2009-03-26 Resolvyx Pharmaceuticals, Inc. Oxylipin compounds for treating autoimmune diseases
CN101888839B (zh) * 2007-10-12 2013-03-20 雷索维克斯药品公司 治疗眼睛病症的omega-3脂肪酸、羟基多不饱和脂肪酸、脂氧素类化合物或脂氧化物类化合物
US20110027841A1 (en) * 2007-12-21 2011-02-03 Martek Biosciences Corporation Method for preparation of oxylipins
CN102083787A (zh) 2008-05-01 2011-06-01 康普雷克萨公司 乙烯基取代的脂肪酸
US20140024713A1 (en) 2008-06-19 2014-01-23 University Of Utah Research Foundation Use of nitrated lipids for treatment of side effects of toxic medical therapies
CA2734870A1 (en) * 2008-08-22 2010-02-25 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for anca-related vasculitis
US8927747B2 (en) 2008-09-16 2015-01-06 The Brigham And Women's Hospital, Inc. 14-hydroxy-docosahexaenoic acid compounds
WO2010039529A2 (en) * 2008-09-23 2010-04-08 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treament of inflammatory disease
EP2415748A4 (de) 2009-02-20 2013-08-07 Univ Tokyo Neue entzündungshemmende verbindungen
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP2459189A4 (de) * 2009-07-31 2013-01-16 Univ Pittsburgh Fettsäuren als entzündungshemmende wirkstoffe
EP2483233A4 (de) 2009-10-02 2013-08-14 Complexa Inc Heteroatom mit substituierten fettsäuren
WO2011097276A1 (en) * 2010-02-02 2011-08-11 Martek Biosciences Corporation Methods and compositions for treating arthritis with docosahexaenoic acid
US9238634B2 (en) 2010-08-19 2016-01-19 The University Of Tokyo Anti-inflammatory metabolite derived from omega-3-type fatty acid
WO2013028501A1 (en) 2011-08-19 2013-02-28 The University Of Utah Research Foundation Combination therapy with nitrated lipids and inhibitors of the renin-angiotensin-aldosterone system
FR2979824A1 (fr) * 2011-09-13 2013-03-15 Vetinnov Composition a usage humain ou veterinaire.
JP5969186B2 (ja) * 2011-09-15 2016-08-17 出光興産株式会社 Ｇｐｒ１１９アゴニスト並びにそれを含むインスリン分泌促進剤、血糖降下剤および糖尿病の治療または予防剤
WO2013044176A2 (en) * 2011-09-23 2013-03-28 University Of Southern California Methods and compositions for the treatment of ischemic stroke
JP6173352B2 (ja) 2012-02-15 2017-08-02 アニダ ファーマ インコーポレイテッド 筋萎縮性側索硬化症の治療方法
EP4205546A1 (de) 2012-05-10 2023-07-05 Solutex NA LLC Öle mit entzündungshemmender wirkung sowie mit natürlichen spezialisierten vorauslösungs-mediatoren und vorprodukten davon
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
ES2948387T3 (es) 2012-08-24 2023-09-11 Sun Pharmaceutical Ind Ltd Formulación oftálmica de ácidos grasos polioxílicos o lípidos polioxílicos y tratamiento de afecciones oculares
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
CA2902232C (en) 2013-02-22 2020-12-29 University Of Southern California Methods for treatment of ophthalmic diseases and disorders
WO2014134184A1 (en) 2013-02-28 2014-09-04 Anida Pharma Inc. Methods of treating ototoxicity
CN105899485B (zh) 2013-11-15 2018-10-19 尊严科学有限公司 多不饱和羟基脂肪酸的药学上可接受的盐
US20150196521A1 (en) * 2014-01-10 2015-07-16 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
RU2714323C2 (ru) 2014-06-04 2020-02-14 ДиЭс БАЙОФАРМА ЛИМИТЕД Фармацевтические композиции, содержащие дглк, и их применение
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
WO2016149582A1 (en) 2015-03-18 2016-09-22 The Forsyth Institute Methods for stabilizing atherosclerotic plaques using lipoxins, resolvins, and analogs thereof
CN113896628A (zh) 2015-05-13 2022-01-07 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
IL280619B2 (en) 2015-07-07 2023-10-01 H Lundbeck As Phosphodiesterase 9 inhibitors with an imidazo triazinon or imidazo pyrazinone skeleton for the treatment of peripheral diseases
EP3861995A1 (de) * 2015-07-21 2021-08-11 Affimune Limited Zusammensetzungen mit 15-hepe zur verwendung in der behandlung oder prävention von neurologischer erkrankung
WO2017041094A1 (en) 2015-09-03 2017-03-09 Solutex Na Llc Compositions comprising omega-3 fatty acids, 17-hdha and 18- hepe and methods of using same
IL258476B2 (en) 2015-10-02 2023-04-01 Complexa Inc Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
WO2017077528A2 (en) * 2015-11-02 2017-05-11 Salzman Lovelace Investments, Ltd. Methods and pharmaceutical compositions for treatment of lung inflammation
DK3373976T3 (da) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Topiske formuleringer og anvendelser deraf
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
WO2017205582A1 (en) 2016-05-27 2017-11-30 Forsyth Dental Infirmary For Children Compositions and methods of treating cancer using lipid agonists and receptors thereof
JP6906047B2 (ja) 2016-06-03 2021-07-21 テティス・ファーマシューティカルズ・エルエルシー 特異的炎症収束性メディエーターの塩に関連する組成物及び方法
CN105924338B (zh) * 2016-06-17 2019-03-01 中科瑞奥能源科技股份有限公司 丁醇尾气回收工艺与系统
EP3475442B1 (de) * 2016-06-23 2024-10-23 The Regents of The University of Michigan 12(s)-hydroxyeicosatriensäure-verbindungen und deren verwendung als therapeutika
US11439615B2 (en) 2017-03-09 2022-09-13 University Health Network Lipoxin and lipoxin analogue mediated neuroprotection and treatments
WO2019182191A1 (ko) * 2018-03-21 2019-09-26 경북대학교 산학협력단 C0x2 아세틸화제를 유효성분으로 포함하는 퇴행성 신경질환의 예방 또는 치료용 약학적 조성물
EP4349403A3 (de) 2018-05-25 2024-06-05 Cardurion Pharmaceuticals, Inc. Monohydrat und kristalline formen von 6-[(3s,4s)-4-methyl-1- (pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-3-tetrahydropyran-4-yl- 7h-imid azo [1,5- a] pyrazin-8-on
MA53501A (fr) 2018-08-31 2021-07-07 Imara Inc Inhibiteurs de pde9 pour le traitement de la drépanocytose
EP3863622B1 (de) 2018-10-09 2024-07-24 University Of Rochester Behandlung von vulvovaginalen störungen
CN113395908B (zh) * 2018-11-30 2024-06-11 赢创运营有限公司 包含巨大芽孢杆菌属益生菌菌株和多不饱和脂肪酸组分的制剂
CA3136137A1 (en) * 2019-04-04 2020-10-08 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Very-long-chain polyunsaturated fatty acids, elovanoid hydroxylated derivatives, and methods of use
KR102442204B1 (ko) * 2019-09-20 2022-09-08 경북대학교 산학협력단 Cox2 단백질의 아세틸화 검출용 항체 및 이의 용도
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
WO2021197639A1 (en) * 2020-04-03 2021-10-07 Afimmune Limited Compositions comprising 15-hepe for treating or preventing hematologic disorders, and/or related diseases
CN112511569B (zh) * 2021-02-07 2021-05-11 杭州筋斗腾云科技有限公司 网络资源访问请求的处理方法、系统及计算机设备
AU2023228890A1 (en) 2022-03-03 2024-10-17 Thetis Pharmaceuticals Llc Cyclodextrin complexes of specialized proresolving mediators
WO2025023183A1 (ja) * 2023-07-21 2025-01-30 国立大学法人大阪大学 炎症性腸疾患を抑制する脂肪酸代謝産物

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US466701A (en) 1892-01-05 Hiram ezkiel payne
US4201211A (en) 1977-07-12 1980-05-06 Alza Corporation Therapeutic system for administering clonidine transdermally
GB2033745B (en) 1978-05-26 1983-08-17 Wellcome Found Fatty acid and derivatives thereof for use in treatment or prophylaxis of thromboembolic conditions
US4567290A (en) 1981-11-27 1986-01-28 Research Corporation Leukotriene analogues
US4442099A (en) 1981-11-27 1984-04-10 Research Corporation Leukotriene analogues
US4576758A (en) 1984-06-01 1986-03-18 The Upjohn Company Anti-inflammatory lipoxin B analogs
US4759880A (en) 1984-09-27 1988-07-26 Research Corporation Alkanoarachidonic acids
GB8507058D0 (en) 1985-03-19 1985-04-24 Efamol Ltd Pharmaceutical & dietary compositions
US4710521A (en) 1986-07-25 1987-12-01 The Celotex Corporation Catalyst mixtures for polyisocyanurate foam
US4810424A (en) * 1987-10-09 1989-03-07 The State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Method for the recovery of 12-(S)-hydroxyeicosapentaenoic acid from the red alga murrayella periclados
US5136501A (en) 1989-05-26 1992-08-04 Reuters Limited Anonymous matching system
CA2082418A1 (en) * 1990-05-07 1991-12-28 Barry I. Bockow Methods and preparations of stable, deodorized oils and pharmaceutical compositions thereof
JPH0425036A (ja) 1990-05-16 1992-01-28 Mitsubishi Electric Corp マイクロ波半導体装置
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US5087790A (en) 1991-06-12 1992-02-11 University Of Southern California Method for olefination of carbonyl compounds using titanocene derivatives
WO1993000084A1 (en) 1991-06-24 1993-01-07 Adelaide Children's Hospital Methods and compositions for treating malaria and other diseases
US5177046A (en) 1991-09-20 1993-01-05 Air Products And Chemicals, Inc. Amine-boron adducts as reduced odor catalyst compositions for the production of polyurethanes
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
US5409955A (en) 1993-05-13 1995-04-25 Bockow; Barry I. Compositions and methods for inhibiting uterine contractility
US5441951A (en) 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
US6887901B1 (en) 1993-06-15 2005-05-03 Brigham & Women's Hospital, Inc. Lipoxin compounds and their use in treating cell proliferative disorders
US5411988A (en) * 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
JP2536436B2 (ja) 1993-11-19 1996-09-18 日本電気株式会社 モ―ルド型半導体装置
US6030917A (en) 1996-07-23 2000-02-29 Symyx Technologies, Inc. Combinatorial synthesis and analysis of organometallic compounds and catalysts
US5752238A (en) 1994-11-03 1998-05-12 Intel Corporation Consumer-driven electronic information pricing mechanism
US5594732A (en) 1995-03-03 1997-01-14 Intecom, Incorporated Bridging and signalling subsystems and methods for private and hybrid communications systems including multimedia systems
US5801280A (en) 1995-04-07 1998-09-01 Sumitomo Chemical Company, Limited Processes for preparing optically active alcohols and optically active amines
US5845265A (en) 1995-04-26 1998-12-01 Mercexchange, L.L.C. Consignment nodes
US5756789A (en) 1995-06-08 1998-05-26 Texaco, Inc. Synthesis of metal--containing aluminophosphates with layered structure
CA2182851A1 (en) 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US5709855A (en) 1995-09-22 1998-01-20 Bockow; Barry I. Compositions of spirulina algae and omega fatty acids for treatment of inflammation and pain
US5870717A (en) 1995-11-13 1999-02-09 International Business Machines Corporation System for ordering items over computer network using an electronic catalog
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
BR9708574A (pt) 1996-04-12 1999-08-03 Searle & Co Derivados benzeno sulfonamida substituídos como pródrogas de inibidores cox-2
US5878400A (en) 1996-06-17 1999-03-02 Trilogy Development Group, Inc. Method and apparatus for pricing products in multi-level product and organizational groups
US5842040A (en) 1996-06-18 1998-11-24 Storage Technology Corporation Policy caching method and apparatus for use in a communication device based on contents of one data unit in a subset of related data units
EP0923544B1 (de) 1996-06-28 2008-10-15 University of Southern California Verfahren zur synthese von aminen und aminosäuren mit organoborverbindungen
US5890138A (en) 1996-08-26 1999-03-30 Bid.Com International Inc. Computer auction system
US5861399A (en) 1996-07-17 1999-01-19 Heart Care Partners Methods and compositions for the rapid and enduring relief of inadequate myocardial function
US5896379A (en) 1996-08-26 1999-04-20 Motorola, Inc. Network node for packet switching with selective data processing and method therefor
US5912006A (en) 1996-08-28 1999-06-15 Eboc, Inc. Compositions and methods for alleviating discomforting menstrual pain
US5946467A (en) 1996-09-20 1999-08-31 Novell, Inc. Application-level, persistent packeting apparatus and method
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
US6201022B1 (en) 1997-03-27 2001-03-13 Myorx, Inc. Methods for treating neurotransmitter-mediated pain syndromes by topically administering an omega fatty acid
US6008205A (en) 1997-04-04 1999-12-28 The Brigham & Women's Hospital, Inc. Polyisoprenyl phosphate stable analogs for regulation of neutrophil responses
US6428990B1 (en) 1997-04-11 2002-08-06 Abbott Laboratories Human desaturase gene and uses thereof
WO1998046588A2 (en) 1997-04-11 1998-10-22 Neorx Corporation Compounds and therapies for the prevention of vascular and non-vascular pathologies
US5878423A (en) 1997-04-21 1999-03-02 Bellsouth Corporation Dynamically processing an index to create an ordered set of questions
US6030715A (en) 1997-10-09 2000-02-29 The University Of Southern California Azlactone-related dopants in the emissive layer of an OLED
US6259699B1 (en) 1997-12-30 2001-07-10 Nexabit Networks, Llc System architecture for and method of processing packets and/or cells in a common switch
AU3843999A (en) 1998-05-07 1999-11-23 Elan Corporation, Plc Solvent/cosolvent free microemulsion and emulsion preconcentrate drug delivery systems
US6377937B1 (en) 1998-05-28 2002-04-23 Paskowitz Associates Method and system for more effective communication of characteristics data for products and services
US6069109A (en) 1998-07-01 2000-05-30 Union Carbide Chemicals & Plastics Technology Corporation Process for the production of half-sandwich transition metal based catalyst precursors
US6336138B1 (en) 1998-08-25 2002-01-01 Hewlett-Packard Company Template-driven approach for generating models on network services
AU1321700A (en) 1998-10-23 2000-05-15 University Of Southern California Combinatorial approach to chiral reagents or catalysts having amine or amino alcohol ligands
US6336105B1 (en) 1998-11-16 2002-01-01 Trade Access Inc. System and method for representing data and providing electronic non-repudiation in a negotiations system
DE19855426A1 (de) 1998-12-02 2000-06-08 Wolfgang Langhoff Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen
US6272474B1 (en) 1999-02-08 2001-08-07 Crisostomo B. Garcia Method for monitoring and trading stocks via the internet displaying bid/ask trade bars
US6397212B1 (en) 1999-03-04 2002-05-28 Peter Biffar Self-learning and self-personalizing knowledge search engine that delivers holistic results
DK1163204T3 (da) 1999-03-18 2005-12-19 Brigham & Womens Hospital Lipoxinforbindelser og deres anvendelse
US6353026B1 (en) 1999-03-18 2002-03-05 Brigham And Women's Hospital Regulation of phospholipase D activity
EP1165066B1 (de) 1999-03-18 2005-11-23 The Brigham And Women's Hospital, Inc. Verwendung von lipoxinen zur inhibierung von tnf-alpha initiierter gegenreaktion
CA2367160A1 (en) 1999-03-18 2000-09-21 Charles N. Serhan Leukotriene b4 receptor transgenic mammals
US6427132B1 (en) 1999-08-31 2002-07-30 Accenture Llp System, method and article of manufacture for demonstrating E-commerce capabilities via a simulation on a network
US6415270B1 (en) 1999-09-03 2002-07-02 Omnihub, Inc. Multiple auction coordination method and system
ATE504557T1 (de) 2000-02-16 2011-04-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
US7700650B2 (en) 2000-03-20 2010-04-20 Trustees Of Boston University Lipoxin analogs and method for the treatment of periodontal disease
US6473314B1 (en) 2000-08-03 2002-10-29 Powerwave Technologies, Inc. RF power amplifier assembly employing multi-layer RF blocking filter
US20020074162A1 (en) 2000-12-15 2002-06-20 Bor-Ray Su Substrate layout method and structure for reducing cross talk of adjacent signals
AU2002252175A1 (en) 2001-03-02 2002-09-19 The Brigham And Women's Hospital Lipoxin analogs as novel inhibitors of angiogenesis
US20040044028A1 (en) 2001-03-30 2004-03-04 Obukowicz Mark G. Combinations of omega-3 fatty acids and cyclooxygenase-2 inhibitors for treatment or prevention of cardiovascular disease and treatment or prevention of cancer
US20030166716A1 (en) 2001-11-06 2003-09-04 Serhan Charles N. Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
WO2003051350A1 (en) 2001-12-18 2003-06-26 The Brigham And Women's Hospital Use of lipoxin analogs to promote cell defense against gram-negative infections
AU2002365167A1 (en) * 2001-12-18 2003-07-09 The Brigham And Women's Hospital Inhibition or prevention of infection by bacteria with epa, dha or analogs
ES2527753T3 (es) * 2002-04-01 2015-01-29 University Of Southern California Eicosanoides trihidroxi poliinsaturados
US7582785B2 (en) * 2002-04-01 2009-09-01 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
WO2003105776A2 (en) * 2002-06-17 2003-12-24 Resolvyx Pharmaceuticals ANALOGUES OF LIPID MEDIATORS DERIVED FROM OMEGA-3 PUFAs AND METHODS OF USE
JP4845378B2 (ja) 2002-08-12 2011-12-28 ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド レソルビン：治療処置用のバイオテンプレート
US7759395B2 (en) 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
US20050075398A1 (en) 2003-08-05 2005-04-07 Bazan Nicolas G. Neuroprotectin D1 protects against cellular apoptosis, stroke damage, alzheimer's disease and retinal diseases
US20050238589A1 (en) 2004-04-14 2005-10-27 Van Dyke Thomas E Methods and compositions for preventing or treating periodontal diseases
US20060293288A1 (en) * 2005-01-07 2006-12-28 Serhan Charles N Use of resolvins to treat gastrointestinal diseases
US8273792B2 (en) 2005-10-03 2012-09-25 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and it's natural stereoisomers
US20100035989A1 (en) 2006-07-19 2010-02-11 Resolvyx Pharmaceuticals, Inc. Compositions and methods for the treatment of mucositis

Also Published As

Publication number Publication date
JP4932116B2 (ja) 2012-05-16
CA2400462C (en) 2011-09-27
JP2016006057A (ja) 2016-01-14
CN100357244C (zh) 2007-12-26
AU3846801A (en) 2001-08-27
EP1762557A3 (de) 2007-11-07
US20100216882A1 (en) 2010-08-26
WO2001060778A2 (en) 2001-08-23
CN102010324A (zh) 2011-04-13
IL151299A0 (en) 2003-04-10
MXPA02007915A (es) 2005-06-20
CN1951899B (zh) 2012-02-01
DE60144401D1 (de) 2011-05-19
JP2015007046A (ja) 2015-01-15
ATE344226T1 (de) 2006-11-15
US6670396B2 (en) 2003-12-30
CA2400462A1 (en) 2001-08-23
JP5973503B2 (ja) 2016-08-23
CN1202068C (zh) 2005-05-18
JP2003525880A (ja) 2003-09-02
JP2010248213A (ja) 2010-11-04
EP1762557B1 (de) 2011-04-06
DE60124256T2 (de) 2007-05-31
EP1296923B1 (de) 2006-11-02
CN1469858A (zh) 2004-01-21
JP2019108348A (ja) 2019-07-04
AU2006225252A1 (en) 2006-11-02
US20070049639A1 (en) 2007-03-01
AU2006225252A2 (en) 2006-11-02
WO2001060778A9 (en) 2002-10-24
AU2009202071B2 (en) 2011-07-07
EP1762557A2 (de) 2007-03-14
AU2009202071A1 (en) 2009-06-18
US7737178B2 (en) 2010-06-15
DE60124256T3 (de) 2012-09-20
EP1296923A2 (de) 2003-04-02
CN1951899A (zh) 2007-04-25
DE60124256D1 (de) 2006-12-14
US20040059144A1 (en) 2004-03-25
AU2001238468B2 (en) 2006-07-06
HK1105948A1 (en) 2008-02-29
EP1296923B3 (de) 2012-04-11
AU2006225252B2 (en) 2009-02-26
CN102010324B (zh) 2014-04-02
WO2001060778A3 (en) 2003-01-16
US8349896B2 (en) 2013-01-08
US20020055538A1 (en) 2002-05-09
US7709669B2 (en) 2010-05-04
US20090149538A1 (en) 2009-06-11
CN1680259A (zh) 2005-10-12
US7053230B2 (en) 2006-05-30

Similar Documents

Publication Publication Date Title
ATE504557T1 (de) Aspirin-ausgelöste lipidmediatoren
NO20041882L (no) Fremgangsmater for behandling av okulare neovaskulaere sykdommer.
DK1268482T3 (da) Pyranoindoler til behandling af glaukom
ITMI20001317A0 (it) Procedimento per la purificazione di diacereina.
NL1014850A1 (nl) Grafkist.
ITTO20001109A0 (it) Composizione farmaceutica per il trattamento anti m. ulcerans.
ITSV20010001U4 (it) Vedi invenzione n. 16 del 1998
ES1049731Y (es) Dispositivo para la administracion de farmacos.
IT1318631B1 (it) Procedimento per la produzione di alfa-olefine.
BR8101523Y1 (pt) disposição construtiva aplicada à cadeira.
BR8001273Y1 (pt) suspensório médico.
TH103000093A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH101000439A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000096A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000094A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH101002917A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000088A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000085A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000084A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000097A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000083A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000082A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000080A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000076A (th) สิทธิบัตรยังไม่ประกาศโฆษณา
TH103000058A (th) สิทธิบัตรยังไม่ประกาศโฆษณา

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties